Cite
HARVARD Citation
Matsumoto, K. et al. (n.d.). A phase 2 study evaluating dose dense AC (ddAC) followed by dose dense paclitaxel (ddP) supported by 3.6 mg peg-filgrastim (ddAC-ddP3.6) for patients (pts) with primary breast cancer (PBC) in Japan -WJOG9016B-. Breast. pp. S15-S16. [Online].